Data compiled by Redley Lamar · ChainSifter Intelligence
8Suppliers
10Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
ZyVersa Therapeutics, Inc. (ZVSA) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
22Total relationships
3Distinct source URLs
9High confidence
0.770Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
ZyVersa Therapeutics, Inc. Suppliers
Ticker
Name
Confidence
Evidence
L-F-RESEARCH-LLC
L-F-RESEARCH-LLC
92%
Form of Warrant pursuant to License Agreement, dated December 15, 2015, by and between L&F Research LLC and Variant Pharmaceuticals, Inc.
INFLAMACORE-LLC
INFLAMACORE-LLC
90%
Form of Warrant pursuant to License Agreement, dated April 18, 2019, by and between InflamaCORE, LLC and Variant Pharmaceuticals, Inc.
VARIANT-PHARMACEUTICALS-INC
VARIANT-PHARMACEUTICALS-INC
90%
Form of Warrant pursuant to License Agreement, dated December 15, 2015, by and between L&F Research LLC and Variant Pharmaceuticals, Inc.
VENDOR
VENDOR
90%
On April 15, 2026, the Company received four additional invoices from the vendor totaling $ 117,525 .
Reciprocal relationship from MS-PK graph: Reciprocal relationship from ZVSA graph: A will adopt this recommendation based on Dr. Thompson’s statement that data supporting the recommendation came from…
A will adopt this recommendation based on Dr. Thompson’s statement that data supporting the recommendation came from over 25 studies conducted all over the globe and involved more than 1,600 patients…
Reciprocal relationship from ORANY graph: Reciprocal relationship from ZVSA graph: lamaCORE may terminate the agreement on 10 days’ notice. Further, the agreement may be terminated by a party upon th…
lamaCORE may terminate the agreement on 10 days’ notice. Further, the agreement may be terminated by a party upon the bankruptcy or insolvency of the other party. Upon any termination of the InflamaC…
ZyVersa Therapeutics, Inc. Customers
Ticker
Name
Confidence
Evidence
L-F-RESEARCH-LLC
L-F-RESEARCH-LLC
85%
we agreed to make additional payments to L&F Research upon the achievement of certain development milestones up to an aggregate maximum of $21.5 million
A will adopt this recommendation based on Dr. Thompson’s statement that data supporting the recommendation came from over 25 studies conducted all over the globe and involved more than 1,600 patients…
Reciprocal relationship from MS-PK graph: Reciprocal relationship from ZVSA graph: A will adopt this recommendation based on Dr. Thompson’s statement that data supporting the recommendation came from…
Reciprocal relationship from ORANY graph: Reciprocal relationship from ZVSA graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from ZVSA graph: Reciprocal relationship from ORAN…
lamaCORE may terminate the agreement on 10 days’ notice. Further, the agreement may be terminated by a party upon the bankruptcy or insolvency of the other party. Upon any termination of the InflamaC…
CAPITAL-RESOURCES
CAPITAL-RESOURCES
62%
velopment expenses consist of costs incurred in the discovery and development of our product candidates, and primarily include: ● expenses incurred under third party agreements with contract research…
INFLAMACORE-LLC
INFLAMACORE-LLC
62%
analysis of 1600 FSGS patients found that a reduction in proteinuria over 24 months was strongly associated with a reduced risk of kidney failure. Based on the data, Parasol recommended proteinuria a…
LARKSPUR-HEALTH-ACQUISITION-CORP
LARKSPUR-HEALTH-ACQUISITION-CORP
62%
t populations not described in the drug’s approved labeling (known as “off-label use”), limitations on industry-sponsored scientific and educational activities, and requirements for promotional activ…
sted the vendor to rescind the retroactive interest on invoices, the Company believes that in accordance with the agreement, the vendor can legally charge the Company interest from the point they wer…
ZyVersa Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
ZVSA-DEBT-13797
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2022-12-12.
ZVSA-DEBT-13796
Warrants outstanding: 1
90%
xbrl warrant detail from xbrl 2025-07-08.
ZVSA-DEBT
Debt stack $1.2M
90%
Market cache reports total debt of $1.2M.
ZyVersa Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for ZyVersa Therapeutics, Inc..
ZyVersa Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
ZVSA-OWNER-GUERRA-ADVISORS-INC
Guerra Advisors Inc
90%
13F overlay lists Guerra Advisors Inc as top holder; 1 tracked holders.
ZyVersa Therapeutics, Inc. Extended Supply Chain Network
